These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32538593)

  • 61. Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience.
    Leon J; Sabbah L; Aubert O; Anglicheau D; Delavenne X; Zuber J; Amrouche L; Scemla A; Giura G; Divard G; Legendre C; Sberro-Soussan R
    Transplantation; 2020 Dec; 104(12):2625-2631. PubMed ID: 32044892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Patients' Perception of Newly Initiated Oral Anticoagulant Treatment for Atrial Fibrillation: an Observational Study.
    Larochelle J; Brais C; Blais L; Perreault S; Farand P; Letemplier G; Beauchesne MF
    J Gen Intern Med; 2018 Aug; 33(8):1239-1241. PubMed ID: 29700791
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Direct oral anticoagulants for patients aged over 80 years in nonvalvular atrial fibrillation: the impact of frailty.
    De Simone V; Mugnolo A; Zanotto G; Morando G
    J Cardiovasc Med (Hagerstown); 2020 Aug; 21(8):562-569. PubMed ID: 32520853
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases.
    Ramagopalan S; Allan V; Saragoni S; Esposti LD; Alessandrini D; Perrone V; Buda S; Stynes G; Toma C; DeSolda F;
    J Comp Eff Res; 2018 Nov; 7(11):1063-1071. PubMed ID: 30101611
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
    Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
    Rozjabek HM; Coleman CI; Ashton V; Laliberté F; Oyefesobi P; Lejeune D; Germain G; Schein JR; Yuan Z; Lefebvre P; Peterson ED
    J Med Econ; 2019 Aug; 22(8):751-759. PubMed ID: 30939954
    [No Abstract]   [Full Text] [Related]  

  • 70. [Stroke after discontinuation of new anticoagulants prior to surgery].
    Myrstad M; Vandvik I; Engebretsen EH; Tveit A
    Tidsskr Nor Laegeforen; 2017 Dec; 137(23-24):. PubMed ID: 29231667
    [No Abstract]   [Full Text] [Related]  

  • 71. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
    Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
    Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 73. What's New in Anticoagulation.
    Razavi JE; Safavi-Naeini P; Razavi M
    Tex Heart Inst J; 2016 Oct; 43(5):419-421. PubMed ID: 27777526
    [No Abstract]   [Full Text] [Related]  

  • 74. SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation.
    Kapoor A; Amroze A; Vakil F; Crawford S; Der J; Mathew J; Alper E; Yogaratnam D; Javed S; Elhag R; Lin A; Narayanan S; Bartlett D; Nagy A; Shagoury BK; Fischer MA; Mazor KM; Saczynski JS; Ashburner JM; Lopes R; McManus DD
    Circ Cardiovasc Qual Outcomes; 2020 Feb; 13(2):e005871. PubMed ID: 32063041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prescribers' views and experiences of using direct acting oral anticoagulants in the management of nonvalvular atrial fibrillation: A survey in remote and rural Scotland.
    Generalova D; Cunningham S; Leslie SJ; Rushworth G; McIver L; Stewart D
    Br J Clin Pharmacol; 2019 Oct; 85(10):2414-2422. PubMed ID: 31313317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
    Steurer J
    Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
    [No Abstract]   [Full Text] [Related]  

  • 77. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):128-129. PubMed ID: 31309231
    [No Abstract]   [Full Text] [Related]  

  • 78. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly.
    Kamath S; Lip GY
    Am J Geriatr Cardiol; 2002; 11(6):357-62; quiz 363-4. PubMed ID: 12417841
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?].
    Caballero Requejo C; Urbieta Sanz E; Iniesta Navalón C; Gascón Cánovas JJ
    Aten Primaria; 2019 Mar; 51(3):184-185. PubMed ID: 30660438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.